Rocket Pharmaceuticals, Inc. (RCKT) Forward P/E Multiple

Rocket Pharmaceuticals delegates the development of gene therapies and testing to third-party contractors, maintaining workforce mobility without the overhead of manufacturing facilities. The business aims to bring therapies for rare pathologies to market by creating single-administration solutions. This chart of the asset's value on GURU.Markets reflects a P/E ratio of 0.00, confirming its status as a developer of innovative DNA-based products.

Rocket Pharma - RCKT Market Cap to Future Earnings Ratio (period 07/04/2022 - 11/14/2026)

Rocket Corp - analytical breakdowns and key metrics (RCKT)

- stock value and consensus price forecast:

Price Chart Rocket Pharmaceuticals, Inc.|RCKT - Analyst Consensus Forecast

- market capitalization details:

Market Capitalization Rocket Pharma|RCKT - Total Enterprise Value

- book capitalization information:

Accounting Value per Share Rocket Pharmaceuticals|RCKT - Total Net Assets|Market Cap to Net Assets Ratio rocketpharma.com|RCKT - Aggregate Asset Value

- debt level and financial liquidity data:

- financial results and valuation multiples details:

RCKT - Net Income|Projected Future Earnings Rocket Pharmaceuticals|RCKT - P/E Multiple|Forward P/E Multiple Rocket Pharmaceuticals Inc|RCKT - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Rocket Pharma|RCKT - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Rocket Pharmaceuticals|RCKT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months rocketpharma.com|RCKT - Net earnings per one share growth for the current year|Earnings growth forecast for next year Rocket Pharmaceuticals

- company sales and revenue statistics:

RCKT - Company Gross Revenue|Projected Sales Volume Rocket Pharmaceuticals, Inc.|RCKT - Market Cap to Revenue|Forward P/S Multiple Rocket Pharma

Fundamental valuation:Rocket Pharmaceuticals, Inc.

Investors seek a balance between asset quality and market value. This indicator compares the current quote with expected net profit to determine whether the business is overbought or undervalued. For Rocket Pharmaceuticals (RCKT), a gene therapy leader with monopoly potential in orphan drugs, this calculation reflects future capitalization following the commercialization of its medicines. Narrowing volatility in the company's forward P/E ratio signals consolidation. The final price action on this chart foreshadows either a powerful growth impulse or a correction.

Analysis of competing companies